AU
UK
CA
NZ
IND
US
Last update at 2026-04-30T21:12:44.213027Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Insider Activity Highlights 3 Undervalued Small Caps In Global Markets
Thu 19 Feb 26, 09:39 AM3 European Stocks Estimated To Be Trading Below Their Intrinsic Value In April 2025
Fri 18 Apr 25, 10:37 AM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 772.00M | 405.00M | 339.00M | 602.00M | 927.20M |
| Minority interest | -2.00000M | -2.00000M | -2.00000M | -3.00000M | -2.00000M |
| Net income | 560.00M | 252.00M | 190.00M | 480.00M | 718.60M |
| Selling general administrative | 611.00M | 595.00M | 588.00M | 542.00M | 388.10M |
| Selling and marketing expenses | 2529.00M | 2489.00M | 2478.00M | 2125.00M | 1485.50M |
| Gross profit | 3977.00M | 3859.00M | 3599.00M | 3427.00M | 2856.60M |
| Reconciled depreciation | 809.00M | 812.00M | 919.00M | 723.00M | 478.40M |
| Ebit | - | 705.00M | 585.00M | 711.00M | 980.80M |
| Ebitda | 993.00M | 1517.00M | 1504.00M | 1434.00M | 1459.20M |
| Depreciation and amortization | - | 812.00M | 919.00M | 723.00M | 478.40M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 993.00M | 721.00M | 585.00M | 808.00M | 996.30M |
| Other operating expenses | 9449.00M | 9565.00M | 9100.00M | 8275.00M | 7009.00M |
| Interest expense | 202.00M | 300.00M | 276.00M | 112.00M | 56.90M |
| Tax provision | 210.00M | 151.00M | 147.00M | 119.00M | 206.60M |
| Interest income | 4.00M | 5.00M | 9.00M | 9.00M | 0.90M |
| Net interest income | -221.00000M | -316.00000M | -276.00000M | -118.00000M | -110.70000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 210.00M | 151.00M | 147.00M | 119.00M | 206.60M |
| Total revenue | 10442.00M | 10286.00M | 9685.00M | 9084.00M | 7992.60M |
| Total operating expenses | 2984.00M | 3138.00M | 3014.00M | 2618.00M | 1873.00M |
| Cost of revenue | 6465.00M | 6427.00M | 6086.00M | 5657.00M | 5136.00M |
| Total other income expense net | -221.00000M | -316.00000M | -246.00000M | -206.00000M | -69.10000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 562.00M | 254.00M | 192.00M | 483.00M | 720.60M |
| Net income applicable to common shares | - | - | - | 480.00M | 718.60M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 12711.00M | 13055.00M | 12745.00M | 13057.00M | 10595.70M |
| Intangible assets | 1998.00M | 2403.00M | 2553.00M | 3127.00M | 2663.40M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 202.00M | 198.00M | - | 0.10M |
| Total liab | 7264.00M | 7746.00M | 7785.00M | 8086.00M | 6304.80M |
| Total stockholder equity | 5443.00M | 5306.00M | 4958.00M | 4968.00M | 4285.20M |
| Deferred long term liab | - | - | - | - | 104.40M |
| Other current liab | 1001.00M | 1039.00M | 882.00M | 268.00M | 302.10M |
| Common stock | 62.00M | 62.00M | 62.00M | 62.00M | 62.40M |
| Capital stock | 62.00M | 62.00M | 62.00M | 62.00M | 62.40M |
| Retained earnings | 2477.00M | 2000.00M | 1819.00M | 1787.00M | 1546.80M |
| Other liab | - | - | - | 661.00M | 604.90M |
| Good will | 5449.00M | 5537.00M | 5303.00M | 5313.00M | 4527.80M |
| Other assets | - | - | - | 146.00M | 123.00M |
| Cash | 813.00M | 331.00M | 272.00M | 376.00M | 345.30M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 3991.00M | 3185.00M | 4305.00M | 4456.00M | 4912.10M |
| Current deferred revenue | - | - | 589.00M | 609.00M | 499.50M |
| Net debt | 3961.00M | 4741.00M | 5017.00M | 5215.00M | 3756.80M |
| Short term debt | 1943.00M | 979.00M | 2403.00M | 2622.00M | 3314.30M |
| Short long term debt | 1780.00M | 803.00M | 2246.00M | 2491.00M | 3193.60M |
| Short long term debt total | 4774.00M | 5072.00M | 5289.00M | 5591.00M | 4102.10M |
| Other stockholder equity | 2904.00M | 2642.00M | 3077.00M | 3119.00M | 2676.00M |
| Property plant equipment | - | - | - | 899.00M | 627.20M |
| Total current assets | 4149.00M | 3929.00M | 3608.00M | 3572.00M | 2750.00M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | -3472.00000M | -2801.60000M |
| Short term investments | - | - | - | - | - |
| Net receivables | 1684.00M | 1672.00M | 1485.00M | 1326.00M | 1216.10M |
| Long term debt | 2490.00M | 3738.00M | 2539.00M | 2744.00M | 563.90M |
| Inventory | 1652.00M | 1724.00M | 1653.00M | 1646.00M | 1188.50M |
| Accounts payable | 1047.00M | 1098.00M | 981.00M | 957.00M | 796.20M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | 602.00M | 435.00M | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 26.00M | 18.00M | 221.00M | 95.00M | 16.10M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 8562.00M | 9126.00M | 9137.00M | 9485.00M | 7845.70M |
| Capital lease obligations | 504.00M | 531.00M | 504.00M | 356.00M | 344.60M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 4.00M | -386.00000M | -306.00000M | -1086.00000M | -2977.90000M |
| Change to liabilities | - | - | - | 0.00000M | 0.00000M |
| Total cashflows from investing activities | -497.00000M | -386.00000M | -317.00000M | -1086.00000M | -2977.90000M |
| Net borrowings | -30.00000M | -424.00000M | -233.00000M | 570.00M | 2389.80M |
| Total cash from financing activities | -305.00000M | -682.00000M | -554.00000M | 134.00M | 2070.90M |
| Change to operating activities | - | - | - | -121.00000M | -184.70000M |
| Net income | 772.00M | 405.00M | 339.00M | 602.00M | 927.20M |
| Change in cash | 482.00M | 59.00M | -104.00000M | 31.00M | 129.30M |
| Begin period cash flow | 331.00M | 272.00M | 376.00M | 345.00M | 216.00M |
| End period cash flow | 813.00M | 331.00M | 272.00M | 376.00M | 345.30M |
| Total cash from operating activities | 1392.00M | 1095.00M | 773.00M | 909.00M | 1010.20M |
| Issuance of capital stock | 0.00000M | -12.00000M | 1.00M | 33.00M | 9.40M |
| Depreciation | 809.00M | 812.00M | 919.00M | 723.00M | 478.40M |
| Other cashflows from investing activities | -250.00000M | -280.00000M | -60.00000M | - | - |
| Dividends paid | 91.00M | 61.00M | 146.00M | 243.00M | 183.00M |
| Change to inventory | -1.00000M | -4.00000M | -30.00000M | -88.00000M | 52.80M |
| Change to account receivables | - | -28.00000M | -129.00000M | - | 18.30M |
| Sale purchase of stock | - | - | - | 1350.00M | 2642.70M |
| Other cashflows from financing activities | -184.00000M | -185.00000M | -166.00000M | -160.00000M | -119.80000M |
| Change to netincome | - | - | - | -172.00000M | -73.20000M |
| Capital expenditures | 284.00M | 297.00M | 226.00M | 282.00M | 143.90M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 29.00M | 44.00M | -64.00000M | -121.00000M | -113.60000M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | 591.00M | 646.00M | -421.00000M | -295.00000M | -281.80000M |
| Free cash flow | 1392.00M | 798.00M | 465.00M | 627.00M | 866.30M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ADDLF AddLife AB (publ) |
- -% | - | 61.76 | - | 6.21 | 11.90 | 0.20 | 1.97 |
| ISRG Intuitive Surgical Inc |
-3.83 0.94% | 402.95 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOF EssilorLuxottica Société anonyme |
-13.86 6.73% | 192.00 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-5.56 5.46% | 96.36 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
-3.27 2.27% | 140.71 | 25.56 | 12.48 | 2.59 | 1.76 | 2.89 | 12.55 |
AddLife AB (publ), together with its subsidiaries, provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory analysis. It offers products and solutions, including analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical services; and in the areas of microbiology, clinical chemistry, coagulation, molecular biology, research, immunology, point-of-care testing, veterinary diagnostics, as well as in the food industry. This segment also provides training programs for its customers. The Medtech segment provides medical device products for surgery, orthopaedics, critical care, endoscopy, wound care, healthcare IT, ophthalmology, home adaptation, and technical aids, as well as surgical procedures, welfare technology, and assistive devices for the elderly and disabled. It operates in Sweden, the United Kingdom, Ireland, Spain, Denmark, Norway, Italy, Finland, Switzerland, Germany, Poland, Austria, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.
Brunkebergstorg 5, Stockholm, Sweden, 103 62
| Name | Title | Year Born |
|---|---|---|
| Mr. Fredrik Dalborg | Pres & CEO | 1972 |
| Mr. Martin Almgren | CFO & Bus. Area Mang. of Medtech | 1976 |
| Ms. Christina Rubenhag | Chief Financial Officer | 1970 |
| Ms. Sophia Dernulf | Head of Financial Control | NA |
| Ms. Ulrika Hellman | Head of Mergers & Acquisitions | 1969 |
| Christian Karlsson | Head of Bus. Devel. | NA |
| Per Wahlstedt | Head of Bus. Control | NA |
| Ms. Jamilah Wass | Group Financial Controller | NA |
| Ms. Lina Åström | Officer of Marketing Communication | NA |
| Mr. Fredrik Dalborg | President & CEO | 1972 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...